-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple sclerosis (MS) is a chronic and disabling disease of the central nervous system (CNS) that usually affects young adults
.
More and more evidences show that environmental factors play an important role in the occurrence and development of MS.
We evaluated the role of circulating cholesterol in a mouse model of experimental autoimmune encephalomyelitis (EAE) disease MS using two different approaches: (1) familial hyperlipidemia caused by low-density lipoprotein receptor (LDLR) deficiency A mouse model of cholesterolemia; (2) the use of the anti-PCSK9 neutralizing antibody alirocumab, which reduces the degradation of LDLR, thereby lowering blood cholesterol levels
.
Results: Elevated blood cholesterol levels caused by LDL receptor deficiency did not aggravate clinical symptoms in EAE mice
.
Furthermore, we observed that the anti-PCSK9 antibody alirocumab did not affect the course of EAE nor modulate the immune response to EAE
Studies have shown that circulating cholesterol does not affect the development of EAE disease
.
It further supports the hypothesis that the beneficial effects of statins cannot be attributed solely to lowering serum cholesterol levels and consequent improvement in hyperlipidemia, which is considered a comorbidity of MS
Source: Vigne S, Duc D, Peter B, et al.
leave a message here